The aim of this study was to perform a head-to-head comparison of efficacy and safety profile between 60 mg denosumab(Den) subcutaneously(SC) per 6 months(Q6M) and 70 mg alendronate(Aln) orally per week(QW) for postme...
详细信息
The aim of this study was to perform a head-to-head comparison of efficacy and safety profile between 60 mg denosumab(Den) subcutaneously(SC) per 6 months(Q6M) and 70 mg alendronate(Aln) orally per week(QW) for postmenopausal women with low bone mineral *** searched electronic databases comparing efficacy and safety of Den SC Q6M and Aln QW in postmenopausal *** primary
暂无评论